Sage Journals: Discover world-class research

Abstract

Limited information is available on the use of botulinum toxin type A injections for children with hereditary spastic paraplegia. This report includes 12 children with hereditary spastic paraplegia (mean age 4.8 ± 2.5 years) who underwent 1 to 6 sessions of botulinum toxin A injections to the hamstrings, adductors and gastrocnemius muscles. Patients showed both improved muscle tone (mean 1.9 ± 0.5 vs 1.18 ± 0.33, P < .001, Ashworth Scale) and motor function (75.3 ± 11.9 vs 77.7 ± 11, P < .001, Gross Motor Function Measure). The effect lasted for a mean of 6.6 ± 3.6 months. During the study period (mean 2.8 ± 1.8 years), the preinjection Gross Motor Function Measure increased (69.2 ± 14.7 vs 78.3 ± 13.5, P = .005), whereas the Ashworth Scale remained stable, suggesting a prolonged effect of botulinum toxin A on motor function. The authors conclude that botulinum toxin A injections to lower limbs of pediatric patients with hereditary spastic paraplegia result in prolonged functional improvement despite the progressive nature of the disease.

Keywords

hereditary spastic paraparesis botulinum toxin A lower extremity

Get full access to this article

View all access options for this article.

References

Harding AE Hereditary ‘‘pure’’ spastic paraplegia: a clinical and genetic study of 22 families. J Neurol Neurosurg Psychiatry . 1981;44:871-883.

McDermott CJ , White K. , Bushby K. , Shaw PJ Hereditary spastic paraparesis: a review of new developments. J Neurol Neurosurg Psychiatry. 2000;69:150-160.

Depienne C. , Stevanin G. , Brice A. , Durr A. Hereditary spastic paraplegias: an update. Curr Opin Neurol . 2007;20:674-680.

Hentati A. , Deng HX , Zhai H. , et al. Novel mutations in spastin gene and absence of correlation with age at onset of symptoms. Neurology. 2000;55:1388-1390.

Appleton RE , Farrell K. , Dunn HG ‘Pure’ and ‘complicated’ forms of hereditary spastic paraplegia presenting in childhood. Dev Med Child Neurol. 1991;33:304-312.

Harding AE Classification of the hereditary ataxias and paraplegias. Lancet. 1983;1:1151-1155.

Bruyn RP The neuropathology of hereditary spastic paraparesis. Clin Neurol Neurosurg. 1992;94(suppl):s16-s18.

Stevanin G. , Ruberg M. , Brice A. Recent advances in the genetics of spastic paraplegias. Curr Neurol Neurosci Rep. 2008;8:198-210.

Depienne C. , Tallaksen C. , Lephav JY , et al. Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases. J Med Genet. 2006;43: 259-265.

10.

Bürger J. , Fonknechten N. , Hoeltzenbein M. , et al. Hereditary spastic paraplegia caused by mutations in the SPG4 gene. Eur J Hum Genet. 2000;8:771-776.

11.

McDermott CJ , Burness CE , Kirby J. , et al. Clinical features of hereditary spastic paraplegia due to spastin mutation. Neurology. 2006;67:45-51.

12.

Meythaler JM , Steers WD , Tuel SM , et al. Intrathecal baclofen use in hereditary spastic paraparesis. Arch Phys Med Rehabil. 1992;73:794-797.

13.

Lambrecq V. , Muller F. , Joseph PA , et al. Intrathecal baclofen in hereditary spastic paraparesis: benefits and limitations. Ann Read-apt Med Phys. 2007;50:577-581.

14.

Ward AB Spasticity treatment with botulinum toxins. J Neural Transm . 2008;115:607-616.

15.

Sarioglu B. , Serdaroglu G. , Tutuncuoglu S. , Ozer EA The use of botulinum toxin type A treatment in children with spasticity. Pediatr Neurol. 2003;29:299-301.

16.

Dunne JW , Heye N. , Dunne SL Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry. 1995;58:232-235.

17.

Rousseaux M. , Launay MJ , Kozlowski O. , Daveluy W. Botulinum toxin injection in patients with hereditary spastic paraparesis. Eur J Neurol. 2007;14:206-212.

18.

Hecht MJ , Stolze H. , Auf dem Brinke M. , et al. Botulinum neuro-toxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia: report of 19 cases. Mov Disord. 2008; 23:228-233.

19.

Russell DJ , Rosenbaum PL , Cadman DT , et al. The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol. 1989;31: 341-352.

20.

Devon RS , Helm JR , Rouleau GA , et al. The first nonsense mutation in alsin results in a homogeneous phenotype of infantile-onset ascending spastic paralysis with bulbar involvement in two siblings. Clin Genet. 2003;64:210-215.

21.

Lesca G. , Eymard-Pierre E. , Santorelli FM , et al. Infantile ascending hereditary spastic paralysis (IAHSP) clinical features in 11 families. Neurology. 2003;60:674-682.

22.

Eymard-Pierre E. , Lesca G. , Dollet S. , et al. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am J Hum Genet. 2002;71:518-527.

23.

Bjornson K. , Hays R. , Graubert C. , et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics. 2007;120:49-58.

24.

Goldstein EM Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol . 2006;21:189-192.

25.

Fattal-Valevski A. , Domenievitz D. , Giladi N. , et al. Long term effect of repeated injections of botulinum toxin in children with cerebral palsy: a prospective study. J Child Orthop. 2008;2: 29-35.

26.

Herrman J. , Geth K. , Mall V. , et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol. 2004;55: 732-735.

Botulinum Toxin Injections for Pediatric Patients With Hereditary Spastic Paraparesis

Abstract

Keywords

Get full access to this article

References